Bladder Cancer Coverage from Every Angle

Jonathan E. Rosenberg, MD, on Enfortumab Vedotin-ejfv vs Chemotherapy in Urothelial Cancer: Practical Clinical Considerations

Posted: Friday, July 8, 2022

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses the implications of phase III findings from the EV-301 trial, which suggest that enfortumab vedotin-ejfv continues to show a significant and consistent survival advantage over standard chemotherapy in patients with previously treated advanced urothelial carcinoma. Dr. Rosenberg outlines patient selection, management of side effects, and ongoing research.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.